Page 302 - IJB-10-2

International Journal of Bioprinting Kidney hydrogel print for renal cancer model

renal cell carcinoma after surgical resection. Urol Oncol. 55. Tani T, Laitinen L, Kangas L, Lehto VP, Virtanen I.
2015;33(2):69e61-10. Expression of E- and N-cadherin in renal cell carcinomas, in
doi: 10.1016/j.urolonc.2014.08.003 renal cell carcinoma cell lines in vitro and in their xenografts.
Int J Cancer. 1995;64(6):407-414.
45. Harada K, Miyake H, Kusuda Y, Fujisawa M. Expression
of epithelial-mesenchymal transition markers in renal cell doi: 10.1002/ijc.2910640610
carcinoma: Impact on prognostic outcomes in patients 56. Gao K, Zhang F, Chen K, et al. Expression patterns and
undergoing radical nephrectomy. BJU Int. 2012;110 prognostic value of RUNX genes in kidney cancer. Sci Rep.
(11 Pt C):E1131-1137. 2021;11(1):14934.
doi: 10.1111/j.1464-410X.2012.11297.x doi: 10.1038/s41598-021-94294-2
46. Rasti A, Madjd Z, Abolhasani M, et al. Cytoplasmic 57. Rooney N, Mason SM, McDonald L, et al. RUNX1 is a driver
expression of Twist1, an EMT-related transcription factor, of renal cell carcinoma correlating with clinical outcome.
is associated with higher grades renal cell carcinomas Cancer Res. 2020;80(11):2325-2339.
and worse progression-free survival in clear cell renal cell doi: 10.1158/0008-5472.CAN-19-3870
carcinoma. Clin Exp Med. 2018;18(2):177-190. 58. Gong D, Zhang J, Chen Y, et al. The m(6)A-suppressed
doi: 10.1007/s10238-017-0481-2
P2RX6 activation promotes renal cancer cells migration and
47. Kugler A, Hemmerlein B, Thelen P, Kallerhoff M, Radzun invasion through ATP-induced Ca(2+) influx modulating
HJ, Ringert RH. Expression of metalloproteinase 2 and ERK1/2 phosphorylation and MMP9 signaling pathway.
9 and their inhibitors in renal cell carcinoma. J Urol. J Exp Clin Cancer Res. 2019;38(1):233-249.
1998;160(5):1914-1918. doi: 10.1186/s13046-019-1223-y
doi: 10.1016/s0022-5347(01)62443-1
59. Ranzuglia V, Lorenzon I, Pellarin I, et al. Serum- and
48. Chambers AF, Matrisian LM. Changing views of the role of glucocorticoid- inducible kinase 2, SGK2, is a novel
matrix metalloproteinases in metastasis. J Natl Cancer Inst. autophagy regulator and modulates platinum drugs
1997;89(17):1260-1270. response in cancer cells. Oncogene. 2020;39(40):
doi: 10.1093/jnci/89.17.1260 6370-6386.
doi: 10.1038/s41388-020-01433-6
49. Xu H, Xu W-H, Ren F, et al. Prognostic value of epithelial-
mesenchymal transition markers in clear cell renal cell 60. Pao AC. SGK regulation of renal sodium transport. Curr
carcinoma. Aging. 2020;12(1):866-883. Opin Nephrol Hypertens. 2012;21(5):534-540.
doi: 10.18632/aging.102660 doi: 10.1097/MNH.0b013e32835571be
50. Sugimoto M, Kohashi K, Itsumi M, et al. Epithelial to 61. Liu Y, Chen J-B, Zhang M, et al. SGK2 promotes
mesenchymal transition in clear cell renal cell carcinoma renal cancer progression via enhancing ERK 1-2 and
with rhabdoid features. Pathobiology. 2016;83(6):277-286. AKT phosphorylation. Eur Rev Med Pharmacol Sci.
doi: 10.1159/000445752 2019;23(7):2756-2767.
doi: 10.26355/eurrev_201904_17549
51. Li X, Ma X, Chen L, et al. Prognostic value of CD44
expression in renal cell carcinoma: A systematic review and 62. Baldewijns MM, van Vlodrop IJ, Vermeulen PB,
meta-analysis. Sci Rep. 2015;5:13157. Soetekouw PM, van Engeland M, de Bruine AP. VHL
doi: 10.1038/srep13157 and HIF signalling in renal cell carcinogenesis. J Pathol.
2010;221(2):125-138.
52. Yao JX, Chen X,. Zhu YJ, Wang H, Hu XY, Guo JM. Prognostic
value of vimentin is associated with immunosuppression doi: 10.1002/path.2689
in metastatic renal cell carcinoma. Front Oncol. 63. Bostrom AK, Lindgren D, Johansson ME, Axelson H. Effects
2020;10:1181-1190. of TGF-beta signaling in clear cell renal cell carcinoma cells.
doi: 10.3389/fonc.2020.01181 Biochem Biophys Res Commun. 2013;435(1):126-133.
doi: 10.1016/j.bbrc.2013.04.054
53. Fiedorowicz M, Khan MI, Strzemecki D, et al. Renal
carcinoma CD105-/CD44- cells display stem-like properties 64. Ma L, Li Y, Wu Y, et al. The construction of in vitro
in vitro and form aggressive tumors in vivo. Sci Rep. tumor models based on 3D bioprinting. Bio-Des Manuf.
2020;10(1):5379. 2020;3(3):227-236.
doi: 10.1038/s41598-020-62205-6 doi: 10.1007/s42242-020-00068-6
54. Katagiri A, Watanabe R, Tomita Y. E-cadherin expression 65. Xu K, Huang Y, Wu M, Yin J, Wei P. 3D bioprinting of
in renal cell cancer and its significance in metastasis and multi-cellular tumor microenvironment for prostate cancer
survival. Br J Cancer. 1995;71(2):376-379. metastasis. Biofabrication. 2023;15(3):035020.
doi: 10.1038/bjc.1995.76 doi: 10.1088/1758-5090/acd960

Volume 10 Issue 2 (2024) 294 doi: 10.36922/ijb.1413